Stock

Consumer groups ask FTC to block Novo Holdings-Catalent deal

By Jody Godoy and Maggie Fick

NEW YORK (Reuters) – Five U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Nordisk (NYSE:NVO)’s controlling shareholder from acquiring contract drug manufacturer Catalent (NYSE:CTLT), saying the deal threatens competition in weight loss drugs and cutting-edge gene therapies.

U.S. Public Interest Research Group, Service Employees International Union (SEIU) and others expressed concerns in a letter to the FTC about the $16.5 billion deal, which Novo Holdings has said would boost supply of Wegovy, Novo’s blockbuster GLP-1 injectable weight loss drug.

Last week, U.S. Senator Elizabeth Warren, a Democrat, called on the FTC to look closely at the deal over similar concerns. 

The deal could constrain options for competitors such as Amgen (NASDAQ:AMGN), Pfizer (NYSE:PFE), Roche, and AstraZeneca (NASDAQ:AZN), who are reportedly developing their own GLP-1 drugs, the groups said.

“”Because of the proposed acquisition, there is a real question of whether these future rivals to Novo will be able to secure the expertise to bring the product to market and have available and qualified capacity to manufacture these products when they commercially launch,” the groups said.

Viking Therapeutics (NASDAQ:VKTX), Structure Therapeutics and Sun Pharma also have GLP-1 drugs in development and could be affected, the groups said.

According to the terms of the deal, Novo Holdings would sell three of Catalent’s factories, where injection pens are filled in sterile conditions, in Italy, Belgium and the United States, on to Novo Nordisk for $11 billion.

Novo Nordisk has said it is committed to honoring existing contracts at the plants, and that it is not aware of any competitive GLP-1 products being manufactured for commercial sale at the three sites.

The groups, which included Consumer Action, Doctors for America and the American Federation of State, County and Municipal Employees (AFSCME) union, also expressed concern that Novo Holding’s ownership could affect Catalent’s capacity to manufacture gene therapies.

AFSCME represents around 1.6 million public sector workers, and SEIU has around 2 million members who work in healthcare, the public sector and property services.

“The competitive concerns here go far beyond existing drugs. We believe the commission should look at the impact on future therapies including gene therapy,” said David Balto, the antitrust lawyer who represents the groups and drafted the letter.

The letter mentioned Catalent’s contracts with Sarepta Therapeutics (NASDAQ:SRPT), to produce its gene therapy Elevidys, and with Novartis (SIX:NOVN), to produce its gene therapy Zolgensma. The Catalent facilities producing these therapies are separate from the three factories that Novo Holdings plans to sell on to Novo Nordisk.

This post appeared first on investing.com

You May Also Like

Editor's Pick

Sen. JD Vance (R-Ohio) and Minnesota Gov. Tim Walz (D) will face off Tuesday night at a CBS News vice-presidential debate in New York....

Latest News

A North Korean defector who escaped to the South more than a decade ago was detained after attempting to cross back into North Korea...

Economy

A U.N. human rights group confirmed Hamas’ leader in Lebanon, who was recently killed by Israeli strikes, was their employee.  Fateh Sherif was killed...

Investing

Astron (ASX:ATR) and Energy Fuels (TSX:EFR,NYSEAMERICAN:UUUU) have completed the establishment of a joint venture to advance the Australia-based Donald rare earths and mineral sands...

Disclaimer: balanceandcharge.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2024 balanceandcharge.com

Exit mobile version